12692056

Source:http://linkedlifedata.com/resource/pubmed/id/12692056

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002199, umls-concept:C0002403, umls-concept:C0008976, umls-concept:C0021747, umls-concept:C0035525, umls-concept:C0087111, umls-concept:C0205263, umls-concept:C0524910, umls-concept:C1280500
pubmed:issue	5
pubmed:dateCreated	2003-4-14
pubmed:abstractText	Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non-responders.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10086636, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10333143, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10379482, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10421669, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10430055, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10462389, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10608783, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10750650, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-10960460, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11003631, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11124841, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11230751, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11254023, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11283865, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-11431744, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-12010649, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-12407587, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-14960538, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-1808228, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-563896, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-7308988, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-7416739, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-8188183, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-9672170, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-9695995, http://linkedlifedata.com/resource/pubmed/commentcorrection/12692056-9819447
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/2985108R
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase, http://linkedlifedata.com/resource/pubmed/chemical/Amantadine, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0017-5749
pubmed:author	pubmed-author:AdinolfiL ELE, pubmed-author:RuggieroGG, pubmed-author:TonzielloAA, pubmed-author:UtiliRR
pubmed:issnType	Print
pubmed:volume	52
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	701-5
pubmed:dateRevised	2010-9-14
pubmed:meshHeading	pubmed-meshheading:12692056-Adult, pubmed-meshheading:12692056-Alanine Transaminase, pubmed-meshheading:12692056-Amantadine, pubmed-meshheading:12692056-Antiviral Agents, pubmed-meshheading:12692056-Drug Administration Schedule, pubmed-meshheading:12692056-Drug Therapy, Combination, pubmed-meshheading:12692056-Female, pubmed-meshheading:12692056-Genotype, pubmed-meshheading:12692056-Hepatitis C, Chronic, pubmed-meshheading:12692056-Humans, pubmed-meshheading:12692056-Interferon-alpha, pubmed-meshheading:12692056-Liver Cirrhosis, pubmed-meshheading:12692056-Male, pubmed-meshheading:12692056-Middle Aged, pubmed-meshheading:12692056-Prospective Studies, pubmed-meshheading:12692056-RNA, Viral, pubmed-meshheading:12692056-Ribavirin, pubmed-meshheading:12692056-Treatment Outcome
pubmed:year	2003
pubmed:articleTitle	Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
pubmed:affiliation	Division of Internal Medicine and Hepatology, Faculty of Medicine, Second University of Naples, Naples, Italy. luigielio.adinolfi@unina2.it
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial